Seizure suppression in kindled rats by intraventricular grafting of an adenosine releasing synthetic polymer

Experimental Neurology

Volumn 160, Issue 1, 1999, Pages 164-174

  Boison, Detlev ^a   Scheurer, Louis ^a   Tseng, Jack L ^b   Aebischer, Patrick ^b   Mohler, Hanns ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

A1 receptor; Adenosine; Cell therapy; Epilepsy; Grafting; Kindling

Indexed keywords

ADENOSINE; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG IMPLANTATION; ELECTROENCEPHALOGRAM; EPILEPTIC DISCHARGE; FOCAL EPILEPSY; KINDLING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE;

EID: 0032728754     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1999.7209     Document Type: Article

References (30)

1. Abdulghani A. S., Attwell P. J. E., Bradford H. F. The protective effect of 2-chloroadenosine against the development of amygdala kindling and on amygdala-kindled seizures. Eur. J. Pharmacol. 326:1997;7-14.
2. Angelatou F., Pagonopoulou O., Maraziotis T., Olivier A., Villemeure J. G., Avoli M., Kostopoulos G. Upregulation of A1 adenosine receptors in human temporal lobe epilepsy: A quantitative autoradiographic study. Neurosci. Lett. 163:1993;11-14.
3. Dragunow M. Adenosine: The brain's natural anticonvulsant. Trends Pharmacol. Sci. 7:1986;128.
4. Dragunow M. Purinergic mechanisms in epilepsy. Prog. Neurobiol. 31:1988;85-108.
5. Dunwiddie T. V., Diao L. Extracellular adenosine concentrations in hippocampal brain slices and the tonic inhibitory modulation of evoked excitatory responses. J. Pharmacol. Exp. Ther. 268:1994;537-545.
6. Dunwiddie T. V., Worth T. Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J. Pharmacol. Exp. Ther. 220:1982;70-76.
7. During M. J., Spencer D. D. Adenosine: A potential mediator of seizure arrest and postictal refractoriness. Ann. Neurol. 32:1992;618-624.
8. Ekonomou A., Angelatou F., Vergnes M., Kostopoulos G. Lower density of A1 adenosine receptors in nucleus reticularis thalami in rats with genetic absence epilepsy. Neuroreport. 9:1998;2135-2140.
9. Elger C. E., Lehnertz K. Seizure prediction by nonlinear time series analysis of brain electrical activity. Eur. J. Neurosci. 10:1998;786-789.
10. Fredholm B. B. Adenosine receptors in the central nervous system. NIPS. 10:1995;122-128.
11. Fredholm B. B. Adenosine and neuroprotection. Int. Rev. Neurobiol. 40:1997;259-280.
12. Glass M., Faull R. L. M., Bullock J. Y., Jansen K., Mee E. W., Walker E. B., Synek B. J. L., Dragunow M. Loss of A1 adenosine receptors in human temporal lobe epilepsy. Brain Res. 710:1996;56-68.
13. Gu J. G., Foga I. O., Parkinson F. E., Geiger J. D. Involvement of bidirectional adenosine transporters in the release of L-(3H)adenosine from rat brain synaptosomal preparations. J. Neurochem. 64:1995;2105-2110.
14. Guieu R., Couraud F., Pouget J., Sampieri F., Bechis G., Rochat H. Adenosine and the nervous system: Clinical implications. Clin. Neuropharmacol. 19:1996;459-474.
15. Guieu R., Dussol B., Halimi G., Bechis G., Sampieri F., Berland Y., Sampol J., Couraud F., Rochat H. Adenosine and the nervous system: Pharmacological data and therapeutic perspectives. Gen. Pharmacol. 31:1998;553-561.
16. Hoffmann D., Wahlberg L., Aebischer P. NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion. Exp. Neurol. 110:1990;39-44.
17. Jacobson K. A., van Rhee A. M. Development of selective purinoceptor agonists and antagonists. Jacobson K. A., Jarvis M. F. Purinergic Approaches in Experimental Therapeutics. 1997;101-128 Wiley-Liss, New York.
18. Lothman E. W., Hatfield J. M., Zorumski C. F., Conry J. A., Moon P. F., Perlin J. B. Kindling with rapidly recurring hippocampal seizures. Brain Res. 360:1985;83-91.
19. McNamara J. O., Bonhaus D. W., Shin C., Crain B. J., Gellman R. L., Giacchino J. L. The kindling model of epilepsy: A critical review. CRC Crit. Rev. Neurobiol. 1:1985;341-391.
20. Murray T. F., Sylvester D., Schultz C. S., Szot P. Purinergic modulation of the seizure threshold for pentylenetetrazol in the rat. Neuropharmacol. 24:1985;761-766.
21. Pak M. A., Haas H. L., Decking U. K. M., Schrader J. Inhibition of adenosine kinase increases endogenous adenosine and depresses neuronal activity in hippocampal slices. Neuropharmacol. 33:1994;1049-1053.
22. Palmer T. M., Stiles G. L. Adenosine receptors. Neuropharmacol. 34:1995;683-694.
23. Racine R. Kindling: The first decade. Neurosurg. 3:1978;234-252.
24. Rosen J. B., Berman R. F. Differential effects of adenosine analogs on amygdala, hippocampus, and caudate nucleus kindled seizures. Epilepsia. 28:1987;658-666.
25. Rudolphi K. A., Schubert P., Parkinson F. E., Fredholm B. B. Neuroprotective role of adenosine in cerebral ischemia. Trends Pharmacol. Sci. 13:1992;439-445.
26. Shorvon S. D. The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia. 37:1996;S1-S3.
27. Simonato M., Varani K., Muzzolini A., Bianchi C., Beani L., Borea P. A. Adenosine A1 receptors in the rat brain in the kindling model of epilepsy. Eur. J. Pharmacol. 265:1994;121-124.
28. Thorn J. A., Jarvis S. M. Adenosine transporters. Gen. Pharmacol. 27:1996;613-620.
29. 2+ channels in supporting hippocampal synaptic transmission. Science. 264:1994;107-111.
30. Winn S. R., Wahlberg L., Tresco P. A., Aebischer P. An encapsulated dopamine-releasing polymer alleviates experimental parkinsonism in rats. Exp. Neurol. 105:1989;244-250.